SCHEMBL16627319

SCHEMBL16627319

CC(c1ccc(C#N)cc1)N1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.61
CHRM2 P08172 2/20 0.51
CHRM1 P11229 2/20 0.51
CYP2D6 P10635 2/20 0.48
SLC1A2 P43004 4/20 0.48
SLC1A3 P43003 3/20 0.48
KCNH2 Q12809 5/20 0.45
SLC1A1 P43005 1/20 0.45
RAB9A P51151 1/20 0.45
HSD11B1 P28845 2/20 0.45
HRH3 Q9Y5N1 2/20 0.44
OPRD1 P41143 1/20 0.43
DPP4 P27487 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM3 P20309 1/20 0.41
DRD1 P21728 1/20 0.41
ADRA1D P25100 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224919 0.86 SLC6A3 (0.50) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL31647252 0.83 OPRD1 (0.62) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL5553163 0.81 SLC6A3 (0.47) CHRM2CHRM1CYP2D6KCNH2HSD11B1
SCHEMBL22899065 0.78 SLC1A2 (0.44) MC4RCHRM2CHRM1CYP2D6SLC1A2
SCHEMBL13563401 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL11148746 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6SLC1A2
SCHEMBL28327890 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL6493679 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL30206300 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6KCNH2
SCHEMBL26199247 0.77 MC4R (0.67) MC4RCHRM2CHRM1CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822656-B1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE CANCER RES INST ROYAL (GB) 2016-10-19 EP disclosed
US-9193689-B2 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-11-24 US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE TNKS, TNKS2, PARP11 MC4R 2553/4885CHRM2 4832/4885CHRM1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.